Sophia Genetics, a Lausanne, Switzerland-based developer of Data-Driven Medicine, raised $13.75m in Series B financing.
The round was led by Dr Mike Lynch’s Invoke Capital, Swisscom and Endeavour Vision.
Led by Jurgi Camblong, CEO, Sophia Genetics is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with accurate and scalable predictive algorithms to diagnose genetic diseases. With this investment, the company gains access to Invoke’s portfolio company Genalys, whose Cambridge-based mathematicians apply big data approaches to genomic information.
In three years, Sophia Genetics has developed bioinformatics pipelines and visualization tools for more than 70 commercial panels, proprietary custom panels and is extending that capability to whole exomes and genomes. The company obtains CE-IVD marking for each supported pipeline and has received ISO 13485 certification.
FinSMEs
08/07/2014